Arbutus Biopharma Corp
Gesloten
4.34 0.46
Overzicht
Wijziging aandelenprijs
24u
Min
4.25
Max
4.38
Inkomsten | 173M 170M |
|---|---|
Verkoop | 178M 179M |
K/W Sectorgemiddelde | 5.398 49.888 |
EPS | 1.19 |
Winstmarge | 94.735 |
Werknemers | 19 |
EBITDA | 177M 169M |
Volgende Winsten | 5 aug 2026 |
|---|
Marktkapitalisatie | 20M 885M |
|---|---|
Vorige openingsprijs | 3.88 |
Vorige sluitingsprijs | 4.34 |
Arbutus Biopharma Corp Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Arbutus Biopharma Corp Prognose
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
